Pyrazolo[1,5-a]pyrimidine PAR2 Inhibitors for Transdermal Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for pruritus and skin-related disorders lack effective PAR2 inhibitors that can provide topical transdermal formulations with minimal skin irritation and excellent absorption.
Innovation Solution
Development of pyrazolo[1,5-a]pyrimidine compounds with specific structural formulas that exhibit PAR2 inhibitory activity, suitable for use in topical transdermal formulations such as ointments, creams, and lotions, which are designed to target PAR2 activation-related symptoms without causing significant skin irritation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for pruritus and skin disorders, then they provide some therapeutic effect, but they cause significant skin irritation and lack effective PAR2 inhibition
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of pyrazolo[1,5-a]pyrimidine compounds through systematic variation of R1, R2, R3, and R4 substituents. This structural optimization achieves potent PAR2 inhibitory activity while reducing skin irritation, resolving the contradiction between therapeutic efficacy and safety
Solution Approach 2:
The patent creates optimized copies of existing PAR2 inhibitor structures by synthesizing multiple analogs with different substituent patterns. These copied and modified structures demonstrate improved pharmacological profiles with enhanced PAR2 selectivity and reduced off-target effects, including minimal skin irritation
2Ease of operation
If topical formulations are designed for transdermal delivery, then they can target skin disorders directly, but achieving excellent absorption without irritation is difficult
Solution Approach 1:
The patent optimizes physical and chemical parameters of the compounds including molecular weight, lipophilicity, and structural features to enhance transdermal penetration. These parameter adjustments enable excellent skin absorption while maintaining low irritation potential, facilitating effective topical formulation development
3Reliability
If current PAR2 inhibitors are used, then they show some inhibitory activity, but they lack the potency and selectivity required for effective treatment
Solution Approach 1:
The patent segments the molecular structure into distinct functional regions: the core pyrazolo[1,5-a]pyrimidine scaffold providing PAR2 binding, and variable R1-R4 substituents optimizing pharmacokinetic properties. This segmentation allows independent optimization of potency and selectivity without excessive overall complexity
Solution Approach 2:
The patent develops a universal pyrazolo[1,5-a]pyrimidine scaffold that serves multiple functions: direct PAR2 inhibition, suitable pharmacokinetic properties for topical delivery, and low irritation potential. This multi-functional platform can be adapted to treat various PAR2-mediated conditions including pruritus, atopic dermatitis, and psoriasis
Data Source
AI summary
Provided is a pyrazolo[1,5-a]pyrimidine compound represented by the general formula [I]:wherein each symbol is as defined in the description, or a salt thereof, having PAR2 inhibitory activity, and a pharmaceutical composition comprising the same.